Search results
H. Michael Shepard. H. Michael Shepard (born 1949) is an American cancer researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award, which he shared with Dennis Slamon and Axel Ullrich for their development of Herceptin [1]
As VP/CSO at Halozyme Therapeutics, Shepard participated in multiple ENHANZE partnerships, and in recruiting collaborations with academic and pharma entities, including important immuno-oncology collaborations with major pharma companies. Shepard was also scientific program leader for Halozyme’s Phase 3 candidate for pancreatic cancer ...
Mar 15, 2024 · In this World View, H. Michael Shepard describes his personal story behind the discovery of trastuzumab, 25 years since its FDA approval for HER2-overexpressing breast cancers.
H Michael Shepard. NB1011, a phosphoramidate derivative of (E)-5- (2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. NB1011 is selectively active against tumor cells ...
Oct 8, 2019 · As an adolescent, H. Michael Shepard was enamored with biology. The interest didn’t feel like a choice; it felt like a compulsion. In September, Shepard and his colleagues received the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking foundational research that led to the creation of Herceptin.
Sep 24, 2019 · Dr. H. Michael Shepard and his team recently won the 2019 Lasker Award which is considered by many to be on par with the Nobel Prize. Shepard is a cancer biologist. Shepard is a cancer biologist.
People also ask
Who is Michael Shepard?
Who is David Shepard?
Who is Dr Shepard?
What did John Shepard do at Genentech?
Sep 10, 2019 · H. Michael Shepard joined Genentech after completing graduate training with George Malacinski and postdoctoral training with Barry Polisky at Indiana University at Bloomington. Polisky was a recent recruit to Indiana from UCSF, and under his tutelage, Shepard worked out mechanisms by which plasmid copy number is regulated by E .
